This week, my young fellow colleague, Diego Useche, post-doc in the lab, is going to present in Copenhagen at the 20th Anniversary conference of DRUID Society our working paper on “Orphan drug designations as valuable intangible assets for IPO investors in pharma-biotech companie”.